Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.64 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310838 | 0.84 | SIGMAR1 (0.58) | MCHR1HRH3SIGMAR1ACHEBACE1 | |
| SCHEMBL5540732 | 0.83 | MCHR1 (0.50) | MCHR1HRH3LMNAACHEBACE1 | |
| SCHEMBL1646804 | 0.82 | HRH3 (0.61) | MCHR1HRH3SIGMAR1KDM4EACHE | |
| SCHEMBL340490 | 0.79 | UBE2M (0.61) | MCHR1HRH3TMEM97ACHEBACE1 | |
| SCHEMBL5862050 | 0.79 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL8037825 | 0.79 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL5577702 | 0.77 | MCHR1 (0.51) | MCHR1HRH3SIGMAR1GAAKDM4E | |
| SCHEMBL19086863 | 0.77 | SIGMAR1 (0.68) | SIGMAR1 | |
| SCHEMBL1425074 | 0.76 | SIGMAR1 (1.00) | MCHR1SIGMAR1SLC6A12TMEM97ATM | |
| SCHEMBL8274001 | 0.76 | MEN1 (0.78) | MCHR1SIGMAR1SLC6A12TMEM97GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | MCHR1 131/4885HRH3 194/4885SIGMAR1 295/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | MCHR1 79/4885HRH3 201/4885SIGMAR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.